PhaseBio Pharmaceuticals Announces Positive Data for Type 2

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
PhaseBio Pharmaceuticals Announces Positive Data for Type 2 Diabetes Treatments PE0139 and PB1023
  • PE0139 was well tolerated; pharmacokinetic / pharmacodynamic profile supports once-weekly dosing
  • PE0139 demonstrated synergistic action with weekly GLP-1 receptor agonist PB1023

MALVERN, Pa., June 7, 2015 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs focused on developing treatments for metabolic and specialty cardiopulmonary disorders, announced positive Phase 1 safety and tolerability data supporting once-weekly dosing of its super-long-acting basal insulin, PE0139, in patients with type 2 diabetes during an oral presentation at the American Diabetes Association 75th Scientific Sessions in Boston. In addition, preclinical study results were presented today that demonstrated strong synergistic action of PE0139 with PhaseBio's weekly GLP-1 receptor agonist PB1023.

PE0139 is in development for once-weekly use in type 2 diabetes. The company's compounds are based on a proprietary Elastin-Like Polypeptides (ELP) technology, which uses recombinant ELP biopolymers to control the half-life, bioavailability and physical characteristics of molecules in order to achieve prolonged exposure and once-weekly dosing.

"We are extremely excited about the pharmacokinetic profile achieved with PE0139 and the potential for once-weekly dosing of basal insulin," said Jonathan P. Mow, Chief Executive Officer of PhaseBio. "The product is liquid stable, ready-to-use and able to be combined with a long-acting GLP-1 such as PB1023, which would make for a convenient product presentation for weekly dosing. We look forward to advancing PE0139 into a Phase 2a multiple ascending dose study later this year."

PE0139, the First Recombinant Fully Human Monomeric Super-Long-Acting Basal Insulin to Display a Sustained Nearly Peakless Insulin Profile Following a Single Subcutaneous Dose in Subjects with T2DM Supporting Weekly Dosing

The safety, tolerability, pharmacokinetic (PK) and preliminary pharmacodynamic (PD) response was evaluated in a randomized, double-blind, placebo-controlled, single ascending dose study of PE0139 in which 37 (24 active and 13 placebo) adults with type 2 diabetes with hemoglobin A1c between 6.0 and 10.0 (inclusive) on a basal insulin plus at least one oral antihyperglycemic agent were enrolled. Subjects were taken off basal insulin one week prior to dosing and were randomized in sequential order to one of four doses (0.05 mg/kg – 1.35 mg/kg).

No dose-limiting toxicities, serious adverse events or hypoglycemia were reported. Related treatment-emergent adverse events occurring in ≥ five percent of subjects were confined to mild injection site erythema (eight percent). PE0139 demonstrated dose-related increases in mean serum drug concentrations, mean decreases in fasting plasma glucose compared to placebo [range -2 to -34 mg/dL, p=0.06], and consistently lower free fatty acid levels compared to placebo [all PE0139 pooled group mean: -0.35 meq/L, p<0.05] measured seven days after dosing. PE0139 was well tolerated and displayed a PK / PD profile supporting once-weekly dosing.

"This is a very exciting first step in the development of a once-weekly insulin formulation, which could be a game changer in the management of diabetes," said John Buse, MD, Ph.D., Chief of the Division of Endocrinology at the University of North Carolina School of Medicine.

Synergistic Action of PE0139, a Super-Long-Acting Basal Insulin, and PB1023 a Weekly GLP-1 Receptor Agonist

A proof-of-principal study in db/db mice was conducted with subcutaneously administered PE0139, PB1023 and a co-formulation to evaluate the effect on fasting plasma glucose (FPG) followed by an intraperitoneal glucose tolerance test. When sub-therapeutic doses of the individual components were administered in a co-formulation, FPG and glucose tolerance were normalized.

Additionally, administration of a co-formulation of PE0139 and a rapid-acting insulin-ELP to STZ-treated mice resulted in a rapid but sustained reduction in FPG. PK analysis indicated that sustained and rapid release ELP fusion proteins are independently released into the circulation.

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel drugs to treat diabetes and cardiovascular dysfunction in patients suffering from rare diseases. The Company's proprietary discovery platform technology uses recombinant ELP biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are tuned for a specific rate of absorption, thereby increasing efficacy and reducing side effects. The Company's lead development candidates are PE0139, a novel super-long-acting basal insulin-ELP fusion for weekly dosing; and PB1046, a weekly VIP receptor agonist for treatment of acute and chronic heart failure and Duchenne muscular dystrophy-associated cardiomyopathy. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA.

Media Contact Annie Starr 6 Degrees Communications 973-415-8838

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 151

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
LONGWELL's New Axial Fan Selection Guide Unveiled

Updated Category News Views 88

LONGWELL's New Fan Brochure Shakes Up Data Center Cooling Alright, let's cut to the chase. LONGWELL, the folks out in Ningbo who live and breathe HVACR and industrial fans, have dropped a new tool that’s going to have OEM engineers raising a glass. This twelve-page axial fan selection guide is a stroke of genius—or at least that's what those of us who've braved the...

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 113

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 89

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 82

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 122

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Asia-Pacific Miracle: New Economic Chapter Unfolds

Updated Category News Views 147

A Fresh Breeze in Asia-Pacific's Sails You ever look around and realize everything's about to change—again? That's Asia-Pacific right now. We're staring down the barrel of a new chapter in what folks are calling the "Asia-Pacific miracle." The text from China Daily paints a picture of a region gearing up to crank the cooperation dial even higher. And where's this...

Continue Reading
Investors, Portillo's Fraud Claims Demand Your Attention

Updated Category News Views 30

Portillo's Investors Caught in a Tough Spot Ah, Portillo's. You thought those hot dogs were the only spicy thing you're biting into? Try these allegations on for size. Investors are biting back with a securities fraud lawsuit, and the details are saltier than a bucket of fries. The folks who held PTLO shares between September 19, 2023, and May 4, 2026, are in the...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 92

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 125

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Earnings Insights: Key Players Ford, McDonald's, and Ferrari

Updated Category News Views 155

Anticipating Earnings Reports from Major Companies As we approach the upcoming earnings reports for several key players in the auto and consumer sectors, attention shifts towards Ford, McDonald's, and Ferrari. Understanding performance in this challenging market has never been more crucial. Each company faces unique circumstances that may influence their financial...

Continue Reading
Parsons Corporation Boosts Share Buyback Authorization to $250M

Updated Category News Views 277

Parsons Corporation Boosts Share Buyback Authorization to $250M Parsons Corporation (NYSE: PSN), a notable player in the national security and global infrastructure sectors, has made a significant decision by increasing its stock repurchase authorization to $250 million. This strategic move, announced recently, is set against the backdrop of robust operating results and...

Continue Reading
India's Foreign Exchange Reserves Show Declining Trends

Updated Category News Views 439

Understanding India's Forex Reserves Decline India's foreign exchange reserves have recently captured attention as they have been on a downward trajectory, marking a notable low. As reported, the reserves fell to $625.87 billion, a level not seen in ten months. This decline represents a significant drop of $8.72 billion in just one week, emphasizing the considerable...

Continue Reading
Efekta Education Ups the Ante with Matt Fisher as CTO

Updated Category News Views 16

AI Veteran Matt Fisher Joins Efekta as CTO You know that moment when an industry veteran steps into a key role and you just feel the tide shifting? That's what we've got on our hands with Efekta Education snapping up Matt Fisher. This isn't just any hire; Fisher's a heavyweight tech player, a regular whiz kid from tech giants like Microsoft and Amazon. He’s been around...

Continue Reading
James River Group Enhances Leadership with New Strategic Appointments

Updated Category News Views 186

James River Group Strengthens E&S Leadership Team PEMBROKE, Bermuda — James River Group Holdings, Ltd. (NASDAQ: JRVR) has taken a significant step forward in its growth strategy with the recent appointments of Georgia Collier and Matt Sinosky to its Excess and Surplus (E&S) leadership team. They will report to Todd Sutherland, the President of E&S, as the company aims...

Continue Reading